FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.

Shun Yamamoto,Ken Kato,Hiroyuki Daiko,Takashi Kojima,Hiroki Hara,Tetsuya Abe,Yasuhiro Tsubosa,Hirofumi Kawakubo,Takeo Fujita,Takashi Fukuda,Shigenori Kadowaki,Takahiro Tsushima,Yasuo Hamamoto,Kengo Nagashima,Kazunori Aoki,Yukihiro Mizoguchi,Shigehisa Kitano,Shinichi Yachida,Satoshi Shiba,Yuko Kitagawa

FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.

2021

202Background: The standard neoadjuvant chemotherapy (NAC) in Japan for locally advanced esophageal squamous cell cancer (ESCC) is CDDP + 5-FU (CF). Immune checkpoint inhibitors (ICI) such as nivol...

Keywords:

Chemotherapy
immune checkpoint inhibitors
Internal medicine
Oncology
Nivolumab
Cohort
locally advanced
Carcinoma
squamous cell cancer
Medicine

Correction
Source
Cite
Save

References

Citations